Get the Stockscreener App
1.07
7.00%
0.07
After Hours:
1.06
-0.01
-0.93%
Lucid Diagnostics Inc stock is traded at $1.07, with a volume of 1.55M.
It is up +7.00% in the last 24 hours and down -18.32% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$1.00
Open:
$1.08
24h Volume:
1.55M
Relative Volume:
1.91
Market Cap:
$204.11M
Revenue:
$4.71M
Net Income/Loss:
$-58.01M
P/E Ratio:
-1.2995
EPS:
-0.8234
Net Cash Flow:
$-46.68M
1W Performance:
+7.96%
1M Performance:
-18.32%
6M Performance:
+1.42%
1Y Performance:
-19.55%
1-Day Range:
$1.0303
$1.11
1-Week Range:
$0.90
$1.11
52-Week Range:
$0.90
$1.70
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.07 | 190.76M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Director buys 245K Lucid Diagnostics (NASDAQ: LUCD) shares in market - Stock Titan
Lucid Diagnostics Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-05-17 - Seeking Alpha
Lucid Diagnostics Inc. (LUCD) reports Q1 loss, misses revenue estimates - MSN
PAVmed Inc (PAVM) Q1 2026 Earnings Call Highlights: Strategic Restructuring and Growth ... By GuruFocus - Investing.com Canada
Upcoming Events - FinancialContent
Maxim Group Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Cuts Target Price to $2 - Moomoo
BTIG Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Maintains Target Price $2.5 - Moomoo
PAVmed (PAVM) Q1 2026 Earnings Transcript - AOL.com
PAVmed (PAVM) Q4 2025 Earnings Transcript - The Globe and Mail
PAVmed Reports Q1 2026 Financial Results, Highlights Progress in Veris Health FDA Submission and Lucid Diagnostics Commercial Expansion - Minichart
Earnings Call Summary | Lucid Diagnostics(LUCD.US) Q1 2026 Earnings Conference - 富途牛牛
PAVmed Reports Wider-than-Expected Q1 2026 Loss - AlphaStreet
Earnings call transcript: PAVmed Inc. Q1 2026 shows restructuring gains By Investing.com - Investing.com Australia
Earnings call transcript: PAVmed Inc. Q1 2026 shows restructuring gains - Investing.com India
Q1 2026 PAVmed Inc Earnings Call Transcript - GuruFocus
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q1 2026 Earnings Call Transcript - Insider Monkey
PAVmed (NASDAQ: PAVM) Q1 2026 results, losses and cash position - Stock Titan
PAVmed Q1: cancer test and implantable monitor push toward coverage, FDA - Stock Titan
Canaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD) - The Globe and Mail
Lucid says $44.8M pro forma cash extends runway well into 2027 as it awaits Medicare LCD - MSN
Lucid Diagnostics Inc.Common Stock (NQ: LUCD - FinancialContent
PAVmed Inc.Series Z Warrant (NQ: PAVMZ - FinancialContent
Lucid Diagnostics Earnings Call Balances Progress, Pressure - TipRanks
PAVmed Reports Business Expansion and Financial Update - Intellectia AI
PAVmed (NASDAQ: PAVM) posts Q1 2026 loss and flags going concern risks - Stock Titan
Lucid Diagnostics Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Lucid Diagnostics Releases Q1 2026 Financial Results - AlphaStreet
LUCD Q1 2026 Earnings Transcript - The Globe and Mail
Lucid Diagnostics Q1 Earnings Call Highlights - Yahoo Finance
LUCD: Q1 revenue reached $1.3M on 3,177 tests, with cash runway extended and Medicare approval pending - TradingView
Lucid Diagnostics Reports Q1 2026 Financial Results: $1.3M Revenue, Strong Cash Position, and Medicare Reimbursement Milestone Progress - Minichart
Earnings call transcript: Lucid Diagnostics Q1 2026: Revenue Miss Despite EPS Match - Investing.com
LUCD: Q1 2026 delivered strong test volume, improved cash, and progress toward Medicare and VA revenue - TradingView
Lucid Diagnostics earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Lucid Diagnostics Reports Q1 2026 Results and Outlook - TipRanks
LUCID DIAGNOSTICS ($LUCD) Releases Q1 2026 Earnings - Quiver Quantitative
Lucid Diagnostics (NASDAQ: LUCD) narrows loss and extends cash runway into 2027 - Stock Titan
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results - marketscreener.com
Lucid Diagnostics (LUCD) Q1 Loss Widening To US$23.6 Million Tests Bullish Growth Narrative - Sahm
Lucid Diagnostics 1Q 2026: Revenue $1.26M, EPS ($0.17) — 10-Q Summary - TradingView
LUCD: Q1 2026 saw higher revenue but continued losses, with future viability hinging on reimbursement and capital - TradingView
Lucid Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lucid Diagnostics (NASDAQ: LUCD) grows Q1 revenue but flags going-concern risk - Stock Titan
TradingKey - tradingkey.com
Fat Pitch FinancialsLucid Diagnostics Inc.Common Stock (Nasdaq:LUCD) Stock Quote - FinancialContent
Lucid Diagnostics Inc. (LUCD) may report negative earnings: Know the trend ahead of next week's release - MSN
Lucid Diagnostics (NASDAQ:LUCD) Stock Rating Lowered by Wall Street Zen - MarketBeat
Lucid Diagnostics Inc. (LUCD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Lucid Diagnostics (LUCD) to Release Earnings on Thursday - MarketBeat
Q3 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):